Le Lézard
Classified in: Health
Subjects: PDT, FDA

FDA Approves Katerziatm, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older


WOBURN, Mass., July 10, 2019 /PRNewswire/ -- Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has approved Katerzia (amlodipine) Oral Suspension, 1 mg/mL, the first and only FDA-approved amlodipine oral suspension. Katerzia is indicated for the treatment of hypertension (high blood pressure) in adults and pediatric patients 6 years of age and older and coronary artery disease in adults.

"We are pleased to announce the FDA approval of Katerzia," said Neal Muni, MD, MSPH, President and Chief Executive Officer of Azurity Pharmaceuticals. "The addition of Katerzia complements our existing pediatric hypertension portfolio and will strengthen the overall offering from Azurity. It is also our first product approval since CutisPharma and Silvergate Pharmaceuticals came together to make Azurity Pharmaceuticals, making this a truly exciting time."

Katerzia offers a ready-to-use (simply shake) oral suspension for children 6 years of age and older that require or prefer an oral liquid option of amlodipine. Appropriate dosing for children is now simple, safe, and effective, while providing the assurance of quality as an FDA-approved product. Katerzia will be readily available through an extensive network of pharmacies and a qualified mail order service. For additional information on Katerzia, please email media@azurity.com.

About Azurity Pharmaceuticals

Azurity Pharmaceuticals is a privately-held, specialty pharmaceutical company formed by the acquisition of Silvergate Pharmaceuticals, Inc. by CutisPharma, Inc., in May 2019.  Azurity focuses on the needs of patients requiring customized, user-friendly drug formulations, especially children and the elderly. Azurity's products, including Epaned® (enalapril maleate) Oral Solution, Qbrelis® (lisinopril) Oral Solution, Xatmep® (methotrexate) Oral Solution, FIRVANQ® (vancomycin hydrochloride) for Oral Solution, and FIRST® Unit-of-Use Compounding Kits, have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by other commercially available therapies. For more information, visit www.azurity.com.

SOURCE Azurity Pharmaceuticals


These press releases may also interest you

at 12:34
The following quote is attributed to Steven M. Solomon, D.V.M., M.P.H., director of the FDA's Center for Veterinary Medicine: "We are committed to working with animal drug sponsors to ensure our review and approval process for new animal drugs is as...

at 12:30
Protenus has been recognized by Modern Healthcare as one of the 2020 Best Places to Work in Healthcare. The complete list of this year's winners, in alphabetical order, is available here. Modern Healthcare will announce the winners' rankings during...

at 12:21
AccuReg, a healthcare technology solutions company, offers hospitals across the country a suite of price transparency solutions that will ensure they meet and exceed the new government compliance requirements that must be implemented by January 2021....

at 12:21
Integral Molecular has launched an expanded panel of SARS-CoV-2 Reporter Virus Particles (RVP), which includes spike protein variants such as D614G and spike protein from other related coronaviruses. These variants will test the breadth of protection...

at 12:18
Athletico Physical Therapy has opened a new location in Delafield on Monday, July 13th and is conveniently located at the corner of 94 and 83, near Chick-Fil-A. Athletico is looking forward to continuing its quality of care throughout the state of...

at 12:05
As the business impact of COVID-19 spreads, the mycoplasma testing market is expected to have Neutral & At Par growth in 2020. The report provides a detailed insight into the mycoplasma testing market in 2020-2024 and forecasts its growth rate and...



News published on 10 july 2019 at 06:00 and distributed by: